SCHEMBL17825314

SCHEMBL17825314

CCC1CCC(c2ccc(-c3cnc(-c4ccc(CC(NC(=O)c5ccc(C(C)(C)C)s5)C(=O)C[C@@H](N)C(=O)O)cc4)nc3)cc2)CC1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 4/20 0.34
▸ TPH1 P17752 3/20 0.34
▸ KIFC1 Q9BW19 2/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ MME P08473 4/20 0.31
▸ PRCP P42785 1/20 0.31
▸ ITGB1 P05556 1/20 0.30
▸ ITGA4 P13612 1/20 0.30
▸ ITGB7 P26010 1/20 0.30
▸ HPGDS O60760 1/20 0.30
▸ MCL1 Q07820 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17825449 0.92 KIFC1 (0.38) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17825447 0.92 KIFC1 (0.38) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17825448 0.92 KIFC1 (0.38) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17834920 0.92 KIFC1 (0.38) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17834549 0.88 MME (0.36) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17968983 0.88 MME (0.36) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17968971 0.88 MME (0.36) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17834602 0.88 MME (0.36) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17834510 0.88 MME (0.36) DGAT1KIFC1ALDH1A1LMNAMAPT
SCHEMBL17825309 0.88 MME (0.36) DGAT1KIFC1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
EP-3230276-A1 GLP-1 RECEPTOR MODULATORS Celgene International II Sarl (CH) 2017-10-18 — — EP disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R DGAT1 2899/4885TPH1 860/4885KIFC1 4738/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R DGAT1 2899/4885TPH1 860/4885KIFC1 4738/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR DGAT1 2729/4885TPH1 831/4885KIFC1 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback